MetaVia Inc., a clinical-stage biotech company focused on cardiometabolic diseases, recently presented updates on its pipeline of next-generation therapeutics targeting obesity and MASH. The company's investigational drug, DA-1726, a novel GLP1R/GCGR dual agonist, is currently in Phase 1 trials and has shown promising results with significant weight loss and reductions in fasted glucose levels. Additionally, DA-1241, targeting MASH, has met its Phase 2a primary endpoint, demonstrating direct hepatic effects and a strong safety profile. MetaVia continues to explore further studies and regulatory interactions for these treatments. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。